EXTL3: A Protein with Potential as A Drug Target Or Biomarker

Target Name: EXTL3

NCBI ID: G2137

EXTL3

EXTL3: A Protein with Potential as A Drug Target Or Biomarker

EXTL3 (Exostosin-like 3) is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. It is a member of the extracellular matrix (ECM) protein family, which includes a variety of proteins that play important roles in tissue repair and regeneration.

One of the unique features of EXTL3 is its ability to induce cell death, either through apoptosis or necroptosis. This property makes it a potential drug target or biomarker for a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

EXTL3 has been shown to play a role in a number of important biological processes in the body, including cell signaling, migration, and invasion. It is a potent inhibitor of the protein kinase B, which is involved in many important cellular processes, including cell growth, differentiation, and survival.

In addition to its role in cell signaling, EXTL3 has also been shown to play a role in the regulation of inflammation and fibrosis. It is a potent inhibitor of the pro-inflammatory protein nuclear factor kappa B (NF-kappa-B), which is involved in the regulation of inflammation and fibrosis.

EXTL3 has also been shown to play a role in the regulation of cell migration and invasion. It is a potent inhibitor of the protein Integrin alpha-2 (ITGA2), which is involved in cell adhesion and migration.

In addition to its role in cell signaling, EXTL3 has also been shown to play a role in the regulation of cell cycle progression. It is a potent inhibitor of the protein cyclin D1 (CDK4), which is involved in the regulation of cell cycle progression.

EXTL3 has also been shown to play a role in the regulation of DNA damage repair. It is a potent inhibitor of the protein homolog of SWR1 (HSR1), which is involved in the regulation of DNA damage repair.

In conclusion, EXTL3 is a protein that has the potential to be a drug target or biomarker for a variety of diseases. Its ability to induce cell death, either through apoptosis or necroptosis, makes it a potential target for cancer and other diseases. Additionally, its role in cell signaling, inflammation, and fibrosis, as well as its role in cell cycle progression and DNA damage repair, make it a potential target for a variety of diseases. Further research is needed to fully understand the role of EXTL3 in these important biological processes and to develop effective treatments for a variety of diseases.

Protein Name: Exostosin Like Glycosyltransferase 3

Functions: Glycosyltransferase which regulates the biosynthesis of heparan sulfate (HS) (PubMed:28132690, PubMed:28148688). Initiates HS synthesis by transferring the first N-acetyl-alpha-D-glucosamine (alpha-GlcNAc) residue (GlcNAcT-I activity) to the tetrasaccharide linker (GlcA-Gal-Gal-Xyl-)Ser core linker (PubMed:11390981, PubMed:35676258). May also transfer alpha-GlcNAc residues during HS elongation (GlcNAcT-II activity) (PubMed:11390981, PubMed:35676258). Lacks glucuronyl transferase II (GlcAT-II) activity (PubMed:11390981, PubMed:35676258). Important for both skeletal development and hematopoiesis, through the formation of HS proteoglycans (HSPGs) (PubMed:28132690, PubMed:28148688, PubMed:11390981, PubMed:22727489, PubMed:35676258). Through the synthesis of HS, regulates postnatal pancreatic islet maturation and insulin secretion (By similarity)

The "EXTL3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about EXTL3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets